IPI 145 (CAS 1201438-56-3)
QUICK LINKS
IPI 145 is a compound utilized in biochemistry and molecular pharmacology research, primarily for its activity as a potent inhibitor of phosphoinositide 3-kinases (PI3K). Studies involving IPI 145 focus on the PI3K signaling pathway, which plays a significant role in cell proliferation, survival, and differentiation. Researchers use this compound to probe the functions of different PI3K isoforms and to dissect the complex signaling networks downstream of PI3K activation. The compound′s ability to selectively inhibit PI3K provides useful for understanding the contribution of this pathway to cellular responses in various experimental models. Moreover, IPI 145 is involved in investigations of intracellular signaling dynamics, where modulation of PI3K activity can have broad implications for the regulation of metabolic and immune responses.
IPI 145 (CAS 1201438-56-3) References
- PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. | Winkler, DG., et al. 2013. Chem Biol. 20: 1364-74. PMID: 24211136
- Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. | Boyle, DL., et al. 2014. J Pharmacol Exp Ther. 348: 271-80. PMID: 24244039
- Two birds with one stone: dual p110δ and p110γ inhibition. | Okkenhaug, K. 2013. Chem Biol. 20: 1309-10. PMID: 24267274
- IPI-145 shows promise in CLL patients. | . 2014. Cancer Discov. 4: 136. PMID: 24501284
- Unmet needs in the treatment of mantle cell lymphoma. | Rosen, ST., et al. 2013. Clin Adv Hematol Oncol. 11: 1-19. PMID: 24893041
- Phosphoinositide 3-kinase inhibitors in lymphoma. | Curran, E. and Smith, SM. 2014. Curr Opin Oncol. 26: 469-75. PMID: 25024054
- Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future. | Desai, AV., et al. 2015. Clin Lymphoma Myeloma Leuk. 15: 314-22. PMID: 25445466
- The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. | Balakrishnan, K., et al. 2015. Leukemia. 29: 1811-22. PMID: 25917267
- Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. | Pillinger, G., et al. 2016. Oncotarget. 7: 39784-39795. PMID: 27174919
- Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ. | Davis, RJ., et al. 2017. Cancer Res. 77: 2607-2619. PMID: 28364000
- Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. | Robak, P. and Robak, T. 2017. Expert Opin Investig Drugs. 26: 1249-1265. PMID: 28942659
- The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis. | Xiao, Y., et al. 2020. Cell Oncol (Dordr). 43: 669-680. PMID: 32382996
- The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. | Maharaj, K., et al. 2020. Blood Adv. 4: 3072-3084. PMID: 32634240
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IPI 145, 5 mg | sc-488318 | 5 mg | $317.00 |